The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / AstraZeneca Lupus Drug Fails to Meet Main Goal in Study

AstraZeneca Lupus Drug Fails to Meet Main Goal in Study

August 31, 2018 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—AstraZeneca’s experimental drug anifrolumab failed to meet its main target in a late-stage clinical study treating patients with moderate to severe lupus, the British drugmaker said on Friday.

You Might Also Like
  • Amgen, UCB Say Osteoporosis Drug Meets Main Goal in Late-Stage Trial
  • Combo Drug for Arthritis & Hypertension Meets Goal in Phase 3 Study
  • FDA Reviewers Question Safety of AstraZeneca’s Gout Drug

AstraZeneca said the drug did not meet the main goal in the final-stage of one of the two clinical trials under the TULIP program, failing to show a statistically-significant reduction in disease activity in patients with systemic lupus erythematosus, commonly known as SLE.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“The result of this trial is disappointing for patients and the lupus community,” says Sean Bohen, AstraZeneca’s Chief Medical Officer.

AstraZeneca has been in a race with GlaxoSmithKline and French biotech company Neovacs to create new treatments for lupus, which affects about 5 million people globally.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Anifrolumab, which is given intravenously, is designed for patients with moderate to severe lupus and works in a different way to GlaxoSmithKline’s Benlysta (belimumab) by targeting interferon, a protein involved in inflammation.

Filed Under: Drug Updates Tagged With: anifrolumab, Lupus, systemic lupus erythematosus (SLE)

You Might Also Like:
  • Amgen, UCB Say Osteoporosis Drug Meets Main Goal in Late-Stage Trial
  • Combo Drug for Arthritis & Hypertension Meets Goal in Phase 3 Study
  • FDA Reviewers Question Safety of AstraZeneca’s Gout Drug
  • AstraZeneca Hit after Psoriasis Drug Linked to Suicide Fears

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)